Pharmacokinetics of a New, Microencapsulated Erythromycin Base after Repeated Oral Doses

Publisher Website
Google Scholar
Abstract
Pharmacokinetics of a new preparation of microencapsulated erythromycin base was studied in 16 healthy subjects. They received 250 mg base 6-hourly or 500 mg 12-hourly for 7 days. The mean maximal serum peaks (.+-. SD) after morning doses on days 1, 2, 3 and 7 were 1.4 .+-. 0.9, 3.2 .+-. 1.1, 3.6 .+-. 0.6 and 3.5 .+-. 1.2 mg/l after the 250 mg dose and 3.2 .+-. 1.5, 3.7 .+-. 2.1, 3.6 .+-. 1.8 and 3.0 .+-. 2.0 mg/l after the 500 mg dose. The mean 24 h urine recoveries were 1.8 and 1.2%, the serum half-lives were (days 1-7) 1.4-2.1 h and 1.9-2.8 h for the 250 mg and 500 mg doses. The mean areas under the serum concentration curves (.+-. SD) were 5.8 .+-. 2.2, 11.9 .+-. 2.2 and 15.3 .+-. 5.1 mg.cntdot.h.cntdot.1-1 after 250 mg and 14.2 .+-. 4.9, 16.4 .+-. 7.6 and 14.3 .+-. 9.0 mg.cntdot.h.cntdot.1-1 after 500 mg on days 1, 2 and 7. The The inter- and intrasubject variability was larger after the 500 mg dose. The pharmacokinetic results indicate that both dosage alternatives are suitable and result in similar steady-state peak levels, but the initial dose should be 500 mg.

This publication has 5 references indexed in Scilit: